Advertisement

Cytokine-Induced Killer cells combined with anti EGFR monoclonal antibody abrogate triple negative breast cancer metastatization

  • R. Sommaggio
    Correspondence
    Corresponding author.
    Affiliations
    Department of Surgery, Oncology and Gastroenterology, Immunology and Oncology Section, University of Padua, Padua, Italy
    Search for articles by this author
  • E. Cappuzzello
    Affiliations
    Department of Surgery, Oncology and Gastroenterology, Immunology and Oncology Section, University of Padua, Padua, Italy
    Search for articles by this author
  • A. Rosato
    Affiliations
    Department of Surgery, Oncology and Gastroenterology, Immunology and Oncology Section, University of Padua, Padua, Italy

    Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy
    Search for articles by this author
      Background: Cytokine-Induced Killer (CIK) cells are an attractive approach for cellular immunotherapy, as they are capable of recognizing tumor cells without the need of antigen-specific priming and can be efficiently and rapidly expanded in vitro. We previously demonstrated that CIK cells can exert ADCC when combined with clinical-grade monoclonal antibodies [1]. In this study, we evaluated the efficacy of this combined therapy in vivo in triple negative breast cancer (TNBC), an aggressive tumor that occurs in approximately 15% of all breast cancer patients. Women with TNBC cannot be treated with hormonal treatments or molecular targeted therapies, as they lack the appropriate targets for these drugs, and thus new therapeutic options are urgently needed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect